+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H2 2020

  • ID: 5146902
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 118 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Apic Bio Inc
  • Evolve Biologics Inc
  • Intellia Therapeutics Inc
  • Liminal BioSciences Inc
  • Moderna Inc
  • Promethera Biosciences SA
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H2 2020, provides an overview of the Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline landscape.

Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline guide also reviews the key players involved in therapeutic development for Alpha-1 Antitrypsin Deficiency (A1AD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1, 16, 3 and 2 respectively.

Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases).
  • The pipeline guide reviews pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Apic Bio Inc
  • Evolve Biologics Inc
  • Intellia Therapeutics Inc
  • Liminal BioSciences Inc
  • Moderna Inc
  • Promethera Biosciences SA
Introduction
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Overview
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Therapeutics Development
Alpha-1 Antitrypsin Deficiency (A1AD) - Therapeutics Assessment

Alpha-1 Antitrypsin Deficiency (A1AD) - Companies Involved in Therapeutics Development

Alpha-1 Antitrypsin Deficiency (A1AD) - Drug Profiles

Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Discontinued Products
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Alpha-1 Antitrypsin Deficiency (A1AD), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Alnylam Pharmaceuticals Inc, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Apic Bio Inc, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Applied Genetic Technologies Corp, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Alpha-1 Antitrypsin Deficiency (A1AD), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Alnylam Pharmaceuticals Inc
  • Apic Bio Inc
  • Applied Genetic Technologies Corp
  • Arrowhead Pharmaceuticals Inc
  • Beam Therapeutics Inc
  • Dicerna Pharmaceuticals Inc
  • Editas Medicine Inc
  • Evolve Biologics Inc
  • Grifols SA
  • Inhibrx Inc
  • Intellia Therapeutics Inc
  • International Stem Cell Corp
  • Kamada Ltd
  • LEXEO Therapeutics LLC
  • Liminal BioSciences Inc
  • Logicbio Therapeutics Inc
  • Mereo Biopharma Group Plc
  • Moderna Inc
  • pH Pharma Co Ltd
  • PlantForm Corp
  • Promethera Biosciences SA
  • Renovion Inc
  • Santhera Pharmaceuticals Holding AG
  • Takeda Pharmaceutical Co Ltd
  • Vera Therapeutics Inc
  • Vertex Pharmaceuticals Inc
  • Z Factor Ltd
Note: Product cover images may vary from those shown
Adroll
adroll